Toward a neuroimaging treatment selection biomarker for major depressive disorder
CL McGrath, ME Kelley, PE Holtzheimer… - JAMA …, 2013 - jamanetwork.com
Importance Currently, fewer than 40% of patients treated for major depressive disorder
achieve remission with initial treatment. Identification of a biological marker that might
improve these odds could have significant health and economic impact. Objective To identify
a candidate neuroimaging “treatment-specific biomarker” that predicts differential outcome to
either medication or psychotherapy. Design Brain glucose metabolism was measured with
positron emission tomography prior to treatment randomization to either escitalopram …
achieve remission with initial treatment. Identification of a biological marker that might
improve these odds could have significant health and economic impact. Objective To identify
a candidate neuroimaging “treatment-specific biomarker” that predicts differential outcome to
either medication or psychotherapy. Design Brain glucose metabolism was measured with
positron emission tomography prior to treatment randomization to either escitalopram …